KYTHERA Biopharmaceuticals Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover
Jun 18, 2015, 11:40 ET
NEW YORK, June 18, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating the board of KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) in connection with a buyout for only $75.00 per share. Concerned KYTH investors are encouraged to contact attorney Hamilton Lindley by clicking here.
The investigation focuses upon the shareholder value of the transaction. Under terms of the proposed agreement, KYTH shareholders would receive only $75.00 per share. The per share offer price would be payable 80% in cash and 20% in new Allergan shares. However, an analyst has set a target price of $85.00 per share. The firm's potential shareholder lawsuit will seek to obtain the highest price reasonably available and that all important information about the deal is disclosed.
Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. KYTH stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] with questions, toll free at (844) 702-2990 or visit http://www.dunnamlaw.com/KYTH.
Find these Waco car accident lawyers on social media on Google+, LinkedIn, Facebook, and Twitter.
SOURCE Dunnam & Dunnam
Share this article